デュラグルチド（遺伝子組換え） 化学特性,用途語,生産方法
説明
Dulaglutide, a GLP-1 receptor agonist that is administered subcutaneously once weekly, has been approved since 2014 for the treatment of adults with type 2 diabetes.
brand name
Dulaglutide is marketed by Eli Lilly as Trulicity.
作用機序
The dulaglutide mechanism of action involves activation of the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in b cells. Thus, it increases intracellular cyclic AMP in these cells, leading to a glucose-dependent release of insulin. Dulaglutide also reduces secretion of glucagon and slows gastric emptying.
Mode of action
The mechanism of action of dulaglutide is as a Glucagon-like Peptide-1 (GLP-1) Agonist. Structurally, dulaglutide is made by replacing Ala with Gly at position 8, Glu with Gly at position 22, and Arg with Gly at position 36 on the GLP-1 (7-37) chain, with an average biological half-life of up to 90h.
デュラグルチド（遺伝子組換え） 上流と下流の製品情報
原材料
準備製品